Eli Lilly Study

0.0(0)
Studied by 0 people
call kaiCall Kai
learnLearn
examPractice Test
spaced repetitionSpaced Repetition
heart puzzleMatch
flashcardsFlashcards
GameKnowt Play
Card Sorting

1/100

flashcard set

Earn XP

Description and Tags

Know these facts and how to answer these questions cold

101 Terms

1
New cards

What does Eli Lilly do

Eli Lilly is a global pharmaceutical company that develops, manufactures, and markets medications for various medical conditions, including diabetes, oncology, and neurodegenerative disorders.

2
New cards

What are Eli Lilly’s most important Products

Their products anchored by its dominant GLP-1 weight loss products including


Ttirzepatide by a wide margin: Monjaro (For type 2 diabetes) and Zepbound (for weight management) together generated ≈ 66% of their latest quarterly revenue.


Foundayo (orforglipron): An emerging oral small-molecule anti-obesity - not generating as much revenue, but just as broadly applicable, and more accessible than the injectable versions.


Jardiance franchise: Diabetes medicines sold through a partnership with Boehringer Ingelheim.


Verzenio: Breast-cancer medicine. Largest oncology product; important diversification from diabetes


Taltz : IL-17A-blocking immunology medicine. Large, established business outside diabetes and obesity

3
New cards

Concentration risk for tirzepitide?

If there was a newer study showing long-term bad effects that would be catestrophic for the company, especially if class action law suits or complete dissolusion of the product happen.

4
New cards

How do Mounjaro, Zepbound, and Foundayo differ?

5
New cards

What are Lilly's latest quarterly revenue, EPS, and growth rates?

Revenue: $24.4 billion - 39% year over year


Diluted EPS (Reported): $7.22 per share, up 16.26% year-over-year.


Quarterly Revenue Growth (YoY): 38.6%.

Quarterly Earnings Growth / EPS Growth (YoY): 16.26% (reported).

6
New cards

How much revenue comes from Mounjaro and Zepbound?

≈ 66%

7
New cards

What is Lilly's current stock price, market cap, and P/E ratio?

trading around $1400,


Market Cap Monday Nov 9th: 1.33 trillion


P/E of around 44.8



8
New cards

How has LLY performed over 1 month, 3 months, and 1 year versus SPY and XLV?

Asset / Index

1-Month Return

3-Month Return

1-Year Return

LLY (Eli Lilly)

+15.37%

+13.97%

+45.91%

SPY (S&P 500 ETF)

~ -1.1%

~ +4.5%

+10.88%

XLV (Healthcare ETF)

~ +9.8%

~ -4.1%

+23.19%


9
New cards

What is Lilly's latest full-year revenue and EPS guidance?

Raised full-year 2026 revenue guidance $91 o $92.0 billion

Updated its non-GAAP EPS guidance to $35.00 to $36.00

10
New cards

What are GLP-1, GIP, and glucagon, and how do the drugs work?

GLP-1: Reduces hunger, slows stomach digestion

GIP: Stimulate insulin release and with GLP-1, can enhance weight loss.

Glucagon: Normally raises blood sugar by signaling the liver to release glucose. Activating its receptor may also increase energy expenditure.

11
New cards

What distinguishes tirzepatide, semaglutide, and orforglipron?

Tirzepatide is made by Lilly: Dual Agonist: GLP-1 + GIP receptors. Sold as Mounjaro/Zepbound.

Semaglutide made by competitor Novo Nordisk: Targets GLP-1 only. Sold as Ozempic/Wegovy.

Orforglipron made by Lilly: Oral GLP-1 drug: Taken daily without injections or food/water restrictions. Sold as Foundayo.

12
New cards

How much average weight loss does each major drug achieve in comparable trials?


Tirzepatide (Zepbound): 21.0% – 22.5%

Semaglutide (Wegovy): 14.9%

Retatrutide 24.2% to 28.3%

13
New cards

What is retatrutide, and how is it different from other GLPs?

Experimental Triple agonist in the GLP 1 family

Showed a signficant edge in weight loss over GLP 1s and dual agonists

Unique in that it suppresses appetite AND actively burns energy/fat via glucagon.

Establishes Lilly’s total efficacy lead over Novo Nordisk and creates a natural pipeline successor to protect revenues against future pricing erosion.

14
New cards

How many U.S. adults have obesity, and how many are overweight?

72% to 74% of U.S. adults are either overweight or have obesity

15
New cards

Who qualifies for weight-loss prescriptions without having obesity?

People in the overweight range, but anyone can actually be prescribed these drugs by doctors—they might just not qualify for insurance coverage.

16
New cards

What is the global eligible population versus the actual paying market?

~2.5 billion adults are overweight or obese, but only a small fraction use GLP-1s. Global sales reached over 70B in 2025, with projections exceeding $100B in 2026. The huge gap between potential patients and actual adoption creates significant growth opportunities for Lilly, especially as prices fall and access expands.

17
New cards

What are credible 2030 obesity-drug revenue forecasts, and why do they differ?

Goldman Sachs $105B

J.P. Morgan / Feb. 2026 $200B

Cheaper pills, competition and generics can expand treatment but lower revenue per patient. Insurance coverage, international adoption and how long patients remain on treatment materially change forecasts

18
New cards

How many Americans currently use GLP-1 drugs for weight loss?

11-12% or 27 million American adults

19
New cards

What barriers prevent eligible patients from obtaining treatment?

Insurance Coverage, affordability, stigma, accessibility in oral form, elligibility

20
New cards

What percentage of patients discontinue GLP-1 treatment within one year?

Roughly half discontinue within one year in real-world studies, rising to about two-thirds in some groups without diabetes.

21
New cards

Why do patients discontinue, and how many eventually restart?

one-third to one-half restart within a year

22
New cards

How have Lilly's revenue and realized prices changed?

Q3 2026: Eli Lilly's third-quarter revenue rose 39% to about $24.4 billion, as a 53% jump in volume swamped a 15% drop in realized prices.

23
New cards

How could lower prices increase Lilly's total revenue?

Lower prices improve affordability and insurance access, resulting in more paying patients.

24
New cards

What are Novo Nordisk's competing drugs, and which indications do they cover?

Ozempic (semaglutide), Wegovy (semaglutide)

25
New cards

Significance of Novo's CagriSema versus tirzepatide trial?

Tirzepatide won the only head-to-head trial. In the 84-week trial, CagriSema lost 23.0% of body weight versus 25.5% for tirzepatide 15 mg. Trial reinforces tirzepatide’s best-in-class position and Lilly’s moat in injectables.

26
New cards

What are Roche, Viking, and Amgen developing?

All three are “fast-followers” chasing Lilly and Novo in the obesity drug market but none have beaten Lilly’s tirzepatide on efficacy, and all are years from market. They are a long-term potential competitive threat, not a near-term one.

27
New cards

How do drug efficacy, safety, convenience, and pricing determine competition?

Efficacy and brand familiarity drive share today. Pricing is near equal, so convenience (Foundayo’s no-fasting pill) and tolerability are the tiebreakers.

28
New cards

How could generic semaglutide outside the U.S. affect industry economics?

Semaglutide patents expired in March 2026 in India, Canada, Brazil, and elsewhere (not the U.S.), cutting prices 50–90% and hurting Novo (a 5–13% 2026 sales hit). Lilly is largely insulated because tirzepatide (expires on May 13, 2036) is a different molecule, but cheap semaglutide could cap what payers abroad will pay for branded obesity drugs, while also expanding the global treated market.

29
New cards

Obesity Drug Shortages

Shortages between 2022 and 2025, FDA declared tirzepatide resolved in December 2024, and semaglutide resolved on February 2025.

Eli Lilly and Novo Nordisk invested tens of billions into new factories, while new daily oral GLP-1 pills bypass the injectable pen bottlenecks that caused the initial crisis.

30
New cards

What happened with Hims & Hers' $49 compounded pill in February 2026?

Hims launched a copycat to Novos pill in February, then pulled it two days later after the FDA threatened action because it was essentially a lookalike pill, along with being unapproved.

Hims stock initially surged over 10% before rapidly reversing and crashing up to 27% following the FDA's crackdown and Novo Nordisk's lawsuit

31
New cards

How does the November 2026 Lilly–Hims partnership change distribution?

Hims patients can now buy Lilly’s drugs at Lilly’s self-pay prices directly on Hims’ platform and Hims pledged never to sell compounded copies of Lilly’s drugs. It gives Lilly a major telehealth channel to push their drugs, as well as reduce potential competition from Hims.

32
New cards

How could Medicare coverage expansion affect volume and net pricing?

The Medicare GLP-1 Bridge is a temporary federal program that provides eligible Medicare beneficiaries with select GLP-1 weight-loss medications for a flat $50 per month. Runs from July 1, 2026, through December 31, 2027.


This opens access to about 20 million seniors, and Lilly captures about 70% of new patients. We saw this quarter that volume is surging (Q3 volume +53%) while net price fell (about -10% U.S., -15% worldwide), and management expects volume to keep outweighing price in 2027. The key risk is the Dec 2027 expiry with no confirmed permanent coverage.

33
New cards

What is the risk of new FDA safety warnings or restrictions?

Lilly's biggest regulatory threat is discovering a serious side effect that limits long-term adoption. However, its established efficacy and growing real-world safety evidence could help mitigate that risk.


On November 9, 2026, the FDA required GLP-1 drugs to add warnings a rare eye condition, but the market shrugged that off and LLY still rallied that day

34
New cards

What happened to Eli Lilly's stock on February 4–5, 2026 and what does it show investors care about?

Feb 4 (+10.3%): Stock surged after strong earnings and 2026 revenue guidance above expectations.

Feb 5 (−7.8%): Stock reversed amid concerns about cheaper competition, specifically from Hims & Hers' $49 pill and discontinued drug programs.

Investors are optimistic about Lilly's growth but highly sensitive to pricing pressure and threats to future earnings.

35
New cards

What happened in Novo's February 23 trial, and why did it benefit Lilly?

Novo's next-generation drug, CagriSema was found to be meaningfully worse than Lilly’s Foundayo, increasing lilly’s competitive advantage and future sales potential

36
New cards

What did the April 1 Foundayo FDA approval change?

Approved Foundayo (orforglipron), Lilly's first oral GLP-1 weight-loss drug.

Convenience: Once-daily pill with no food or water restrictions, unlike Novo's oral Wegovy.

37
New cards

What was significant about the October 29 earnings report and stock reaction?


August 5 earnings: Q2 revenue surged 48%

Sales volume rose 60%, outweighing a 13% decline in realized prices.

Revenue guidance raised: From $82–85B to $85–87B for 2026.

EPS guidance: Narrowed from $35.50–37.00 to $35.50–36.50 due to acquisition-related research charges, despite stronger underlying growth.

Pitch takeaway: Lilly demonstrated that expanding patient demand can more than offset falling drug prices, supporting its long-term growth thesis.

38
New cards

What is the latest regulatory status and timeline for retatrutide?

- Current status: Phase 3 clinical trials; not yet FDA-approved.

- Trial results: Multiple successful Phase 3 trials, with weight loss reaching approximately 25–28% in certain obesity trial analyses.

- FDA submission: Lilly plans to file for approval in Q1 2027 (January–March).

- Potential approval: Late 2027 or 2028, depending on FDA review and regulatory delays; no official approval date exists.

- Pitch takeaway: Retatrutide could become Lilly's next major growth driver, potentially offering greater weight loss than Zepbound and expanding treatment opportunities.

39
New cards

What did the November 9 Foundayo sleep-apnea trial show?

Foundayo's November 9 trial showed up to a 44% reduction in sleep-apnea problems, potentially expanding Lilly's market beyond weight loss, increasing prescriptions and insurance coverage, and driving long-term revenue growth.

40
New cards

What are the next major earnings, FDA, trial, and investor-event dates?

Dec 7, 2026 Lilly Innovation Day Pipeline updates, new drugs, and long-term growth opportunities.

By end of 2026 Foundayo sleep-apnea FDA submission planned could expand the oral drug's indications and insurance coverage.

Q1 2027 Retatrutide FDA submission planned

~Feb, 2027 Q4 2026 earnings Watch GLP-1 sales, pricing, patient growth, margins, and 2027 guidance.

41
New cards

What pipeline programs outside obesity could become meaningful businesses?

Lilly's newest oncology, immunology, and neuroscience products doubled revenue year over year in Q3 2026, suggesting the company could develop major revenue streams beyond GLP-1 drugs and reduce its dependence on obesity treatments.

42
New cards

What are Lilly's forward P/E and price-to-sales ratios versus peers?

Company Forward P/E Price/Sales

Eli Lilly (LLY) 30.6× 14.7×

Novo Nordisk (NVO) 12.1× 3.5×

AbbVie (ABBV) 18.8× 7.8×

Johnson & Johnson (JNJ) 25.2× 6.8×

AstraZeneca (AZN) 16.8× 4.6×

Merck (MRK) 17.5× 5.4×


Investors pay roughly 31 times Lilly's expected earnings and 15 times annual sales, reflecting expectations of exceptional GLP-1 growth, expanding access, and pipeline success.

43
New cards

How much future revenue and earnings growth does the consensus expect?

Analysts expect Lilly's revenue to grow roughly 55% from 2026 to 2030, while earnings per share more than double. This reflects expectations of expanding GLP-1 sales, improving margins, and new products.

44
New cards

5 pillars of the the bull case for Lilly over the next 12–24 months?

1. Massive untapped GLP-1 market


2. Lower prices could actually increase revenue



3. Foundayo expands the market rather than merely replacing existing injectable users


4. Retatrutide could strengthen Lilly's competitive advantage


5. Lilly could become more than an obesity company



45
New cards

Lilly expanded bear case

Five major risks and supporting evidence

1. Extremely expensive valuation

- Lilly trades around 30× forward earnings, compared with roughly 12× for Novo Nordisk.

- Investors already expect Lilly's earnings to grow dramatically through 2030.

- Bear argument: Even strong earnings growth may not justify the stock price if results merely meet expectations.


2. Falling GLP-1 prices could eventually overwhelm volume growth

- In Q3 2026, Lilly's realized prices declined 15%, while sales volume rose 53%.

- Competition, insurance negotiations, and lower-cost treatments could intensify pricing pressure.

- Bear argument: Lilly must keep attracting substantially more patients just to offset declining revenue per treatment.


3. Heavy dependence on Mounjaro and Zepbound

- Combined Q3 2026 sales were approximately $16.1 billion, or 66% of total company revenue.

- Bear argument: A competitive breakthrough, unexpected safety problem, or demand slowdown in GLP-1s could disproportionately damage Lilly's growth.


4. New drugs might not meet expectations

- Foundayo generated $184 million in Q3 2026 revenue, below analyst estimates despite encouraging underlying demand.

- Retatrutide still faces regulatory and commercialization risks.

- Bear argument: Investors may be assigning substantial value to treatments whose eventual sales and profitability remain uncertain.

Reuters


5. Strong headline results can obscure underlying risks

- Q3 revenue included approximately $900 million in favorable benefits, including milestone payments and rebate adjustments.

- Lilly raised revenue guidance but lowered reported non-GAAP EPS guidance because of acquired research-and-development charges.

- Bear argument: Investors should separate recurring operating growth from temporary accounting benefits and acquisition costs.


6. Competition is already showing up in the oral GLP-1 market

- Novo's Wegovy pill generated roughly $811 million in Q3, versus $184 million for Lilly's Foundayo.

- Prescription tracking also shows Novo maintaining a substantial early lead in oral obesity treatments.

- Bear argument: Lilly's dominance in injectable treatments may not automatically translate into dominance in pills.


46
New cards

What would make you change your own investment thesis?

  1. Volume growth slows: Patient growth no longer offsets declining GLP-1 prices, weakening revenue and margins.

  2. Competition strengthens: Novo or another competitor develops a substantially better or cheaper treatment, threatening Lilly's market share.

  3. Pipeline disappoints: Retatrutide fails to gain FDA approval or Foundayo adoption falls short of expectations.

  4. Safety concerns emerge: Serious adverse effects lead to FDA restrictions or reduced prescriptions.

  5. Valuation becomes unjustifiable: Earnings growth slows below consensus, making Lilly's premium P/E difficult to sustain.


47
New cards

How do interest rates, sector rotation, and risk appetite affect Lilly's valuation?

Interest rates: Higher rates generally hurt Lilly's valuation because investors discount its expected future earnings more heavily. Lower rates can support a higher P/E multiple.

Sector rotation: When investors move into healthcare for its defensive characteristics, Lilly may benefit. However, Lilly's premium valuation makes it behave partly like a growth stock, not just a defensive pharmaceutical company.

Risk appetite: When investors are optimistic, they're more willing to pay high multiples for Lilly's future growth. During market uncertainty, they may demand cheaper valuations.

48
New cards

How would you explain Lilly in 30 seconds to someone unfamiliar with pharmaceuticals?

Eli Lilly is one of the world's largest pharmaceutical companies (who discover, develop, manufacture and sell drugs), best known for Mounjaro and Zepbound, its diabetes and weight-loss drugs. Founded in 1876 and headquartered in Indianapolis, they are best known for pioneering treatments for some of the world’s biggest health challenges. Most famously being the first company to mass-produce insulin in the 1920s. Today, they focus heavily on major health challenges like diabetes, obesity, cancer, Alzheimer’s disease, and immune system disorders. In short, they spend billions of dollars on science and clinical trials to turn new biological discoveries into everyday medicines you get at the pharmacy.

49
New cards

What are the next catalysts for Lilly?

December 7, 2026 – Lilly Innovation Day: Major updates on next-generation obesity drugs, Alzheimer's treatments, and oncology pipelines.

Q4 2026 – Novo Nordisk CagriSema FDA Decision: Approval could introduce a major new competitor to Zepbound.

Q4 2026 – Foundayo FDA Milestones: Potential diabetes approval and planned sleep-apnea submission could expand Lilly's market.

Ongoing through 2027 – GLP-1 Prescriptions and Medicare Access: Rising patient volumes and broader coverage could offset falling drug prices.

February 2027 (estimated) – Lilly Q4 Earnings: 2027 revenue guidance, margins, and GLP-1 sales will test whether Lilly can sustain its growth.

Q1 2027 – Retatrutide FDA Submission: A major step toward approval of Lilly's potentially more effective next-generation obesity drug.

50
New cards

What are SPY and XLV trading at?

Check daily.

51
New cards

Lilly Competitors within US

Novo Nordisk (NVO)

Wegovy, Ozempic, oral Wegovy, CagriSema pipeline

Biggest direct GLP-1 rival

Amgen (AMGN)

MariTide (in development)

Potential longer-lasting obesity treatment

Viking Therapeutics (VKTX)

VK2735 (in development)

Potential injectable and oral GLP-1 competition

Structure Therapeutics (GPCR)

Aleniglipron (in development)

Potential oral obesity-drug competitor

Pfizer (PFE)

Oncology, immunology, metabolic-disease research

Broad pharmaceutical competition

Merck (MRK)

Oncology and cardiometabolic treatments

Competes across multiple therapeutic areas


52
New cards

Biggest competitors worldwide

Top threat Novo Nordisk


Emerging threats

Amgen


Roche


Pfizer


Potential challenger

Viking Therapeutics

53
New cards

Lilly Earnings date

Earnings Date: Oct 29, 2026

54
New cards

Eli Lilly Multiples

Forward P/E 30.6×

Trailing P/E 46.5×

EV/EBITDA

Price/Sales (TTM)

55
New cards

Novo Nordisk Multiples

Forward P/E 12.1×

Trailing P/E 10.7×

EV/EBITDA 7.0×

Price/Sales (TTM) 3.6×

56
New cards

What does the gap between trailing and forward P/E reflect

Expectations of future earnings growth.

57
New cards

What does it mean if Forward P/E is lower than Trailing P/E

This means analysts expect the company's earnings per share (EPS) to increase over the next 12 months compared to the past 12 months

58
New cards

What does it mean if Forward P/E is lower than Trailing P/E

This means analysts expect the company's earnings to decrease or normalize downward in the coming year.

59
New cards

How does Eli Lilly communicate with investors

eyond SEC filings and earnings calls, Lilly announces:

- Clinical milestones from Drug trials and pipeline progress.

- Innovation events: R&D days and medical conferences.

60
New cards

Since 2020, how much manufacturing investment has Lilly accounced.

Over $55 Billion, with over 50 B in the US

61
New cards

Lilly’s annual CapEx in 2025

$7.8 Billion, up from $5.1 B in 2024 with elevated spending near term

62
New cards

Why is Lilly investing so much in manufacturing

To meet obesity-drug demand, avoid shortages, expand supply and prepare for future drug launches

63
New cards

What major Indiana manufacturing investment did Lilly announce in May 2026?

Another $4.5 billion across its Lebanon sites, bringing Indiana manufacturing commitments above $21 billion since 2020.

64
New cards

What is Lilly building in Houston, Texas, and why?

A $6.5 billion active pharmaceutical ingredient (API) manufacturing plant, including production for its oral GLP-1 drug Foundayo (orforglipron).

65
New cards

What is Lilly's $3.5 billion Pennsylvania plant intended to produce?

Next-generation injectable obesity drugs and delivery devices, including investigational retatrutide.

66
New cards

What is Lilly's new $5 billion Virginia manufacturing facility for?

Advanced medicines, including antibody-drug conjugates for cancer. Construction began in October 2026.

67
New cards

How can manufacturing expansion strengthen Lilly's competitive position?

More reliable supply, higher potential sales volume, fewer shortages, and manufacturing capacity for new drug launches.

68
New cards

What is the main financial risk of Lilly's huge CapEx commitments?

Near-term free-cash-flow pressure and execution risk if manufacturing capacity exceeds demand or future drug launches disappoint.

69
New cards

What is Lilly's expected revenue growth trajectory through 2030?

Approximately 40% in 2026, 17% in 2027, 11% in 2028, gradually slowing to 8% by 2030. 2026 Lilly management guidance; 2027–2030 analyst estimates from Bespoke.

70
New cards

What are Lilly's projected revenues for 2026–2030?

- 2026: $91.5B

- 2027: $107B

- 2028: $119B

- 2029: $130B

- 2030: $141B

Basis: Lilly's 2026 revenue guidance of $91–92B; 2027–2030 rounded analyst estimates from Bespoke. The 2027 figure is approximately $106B in that source.

71
New cards

What are Lilly's projected adjusted EPS figures through 2030?


  • 2026: $35.50

  • 2027: $50

  • 2028: $57

  • 2029: $66

  • 2030: $72


72
New cards

Why could Lilly's earnings grow faster than its revenue?

Operating leverage, manufacturing efficiency, and higher-margin products could increase profitability as revenue grows.

73
New cards

Why might Lilly's P/E multiple decline even as earnings increase?

As growth slows and the company matures, investors may pay a lower premium for each dollar of earnings (multiple compression).

74
New cards

What is a plausible P/E multiple for Lilly by 2030?

20–25× earnings, compared with approximately 30× forward earnings in November 2026.

75
New cards

What happens to Lilly's P/E by 2030 if its stock price remains at $1,433?

It declines to approximately 20×, assuming 2030 EPS reaches $72.

Basis: $1,433 ÷ $72 = 19.9×. The EPS figure is a rounded analyst estimate.

76
New cards

What is Lilly's implied 2030 stock price in the base case?

$72 EPS × 23× P/E = $1,656, approximately 16% total upside, excluding dividends.

Basis: Analyst EPS estimate combined with an assumed 23× P/E.

77
New cards

What are the bear, base, and bull valuation scenarios for 2030?

  • Bear: $60 EPS × 18× = $1,080 (−25%)

  • Base: $72 EPS × 23× = $1,656 (+16%)

  • Bull: $90 EPS × 25× = $2,250 (+57%)


78
New cards

What are Lilly's main growth drivers for 2027–2028?


Mounjaro and Zepbound sales growth, international expansion, increased manufacturing capacity, and oral GLP-1 adoption.

79
New cards

What are Lilly's potential growth drivers for 2028–2030?

Retatrutide commercialization, additional pipeline drugs, and increased production from new manufacturing facilities.

80
New cards

How could Lilly increase revenue despite falling drug prices?

By increasing prescription volume enough to offset lower prices. Greater affordability could also expand the number of patients. Also, their more accessible versions of the drugs through pills increase patient accessibility and interest.

81
New cards

What happened to Lilly's volume and realized prices in Q3 2026?

Volume increased approximately 53%, while realized prices declined approximately 15%.

Basis: Lilly's Q3 2026 earnings release.

82
New cards

What is the biggest risk to Lilly's long-term valuation?

Earnings growth disappoints while investors reduce the P/E multiple they're willing to pay, potentially causing the stock to fall despite revenue growth.

83
New cards

Why isn't rapid growth in the obesity-drug market alone enough to justify buying Lilly?

Because investors already expect substantial growth. A bullish pitch must explain why Lilly will outperform the earnings expectations reflected in its current valuation.

84
New cards

What is Lilly's illustrative 12-month price target using 2028 earnings?

$57 projected 2028 EPS × 28× forward P/E = approximately $1,600, or 12% upside from $1,433.

85
New cards

What investment horizon makes sense for Lilly's long-term growth thesis?

Three to four years (2029–2030), allowing time for manufacturing expansion, international growth, and pipeline commercialization.

86
New cards

What is the central question in Lilly's valuation?

Can earnings grow fast enough to offset declining valuation multiples while still delivering attractive shareholder returns?

87
New cards

Why might Lilly's 2027 adjusted EPS growth overstate underlying operational improvement?

2026 earnings include significant acquired R&D charges, making the comparison unusually favorable.

88
New cards

What would justify a more bullish Lilly valuation than the base case?

Faster oral GLP-1 adoption, successful retatrutide commercialization, stronger margins, or greater market share than analysts expect.

89
New cards

Who leads the oral obesity market, and what are the latest prescription trends?

Novo Nordisk’s Wegovy pill (oral semaglutide). It launched Jan 5, 2026, four months before Lilly’s Foundayo (orforglipron).

90
New cards

What is the oral GLP-1 prescription share?

About 75% Novo and 25% Lilly

91
New cards

Is Lilly’s Foundayo gaining ground on Novo’s Wegovy pill in weekly prescriptions?

Yes, but slowly. Wegovy pill scripts are flat near 180K, while Foundayo’s are up about 9x since launch. The ratio went from about 4-to-1 in early September to about 3-to-1 in October.

92
New cards

Why is Novo’s Wegovy pill ahead of Lilly’s Foundayo in prescriptions?

Brand familiarity: five years as an injectable, plus heavy advertising

Efficacy: about 14% weight loss, versus 10–12% for Foundayo

Head start: four months

93
New cards

What are Eli Lilly’s selling points for Foundayo against Novo’s Wegovy pill?

No fasting or empty-stomach requirement

Same $149/month cash-pay starter price as Novo

About 4 in 10 new oral-obesity patients choose Foundayo (per Lilly’s CFO)

94
New cards

How did Eli Lilly’s Foundayo perform financially in Q3 2026?

Sales of $184M (Q2: $98M), versus consensus of about $217M

Lilly blames about $30M of launch inventory booked in Q2

U.S. demand excluding inventory rose from $37M to over $120M

95
New cards

How much does Foundayo’s weaker-than-expected launch matter to the Eli Lilly (LLY) stock thesis?

Not much. Foundayo is a rounding error against $24.4B of Q3 2026 revenue, which was up 39% year over year. The stock rose on the beat-and-raise, driven by Mounjaro and Zepbound.

96
New cards

What is the one-line takeaway on Eli Lilly’s position in the oral obesity market for a stock pitch?

“Novo leads the pill race about 3-to-1 on brand and head start, but the gap is narrowing. For LLY, the pill is defensive option value. The thesis is tirzepatide plus the pipeline.”

97
New cards

Bull case 5 pillars expanded:

1. Massive untapped GLP-1 market

Only a fraction of potentially eligible patients currently receive GLP-1 treatments. Lower prices, better insurance coverage, and international expansion could bring millions of additional patients into the market.

2. Lower prices could actually increase revenue

Lilly's Q3 2026 sales volume grew 53%, more than offsetting a 15% decline in realized prices, producing 39% revenue growth. This supports the argument that higher patient volumes can outweigh pricing pressure, although the quarter included some nonrecurring benefits.

3. Foundayo opens a new segment

Lilly's oral GLP-1 could attract patients who dislike injections, expanding the market rather than merely replacing existing Zepbound users. Watch pill adoption, retention, and competition with Novo's oral products.

4. Retatrutide could strengthen Lilly's competitive advantage

Retatrutide, Lilly's triple-agonist drug, has demonstrated promising Phase 3 results. A planned Q1 2027 FDA submission could bring investors closer to another major obesity treatment, although approval is not guaranteed.

5. Lilly could become more than an obesity company

Its newer oncology, immunology, and neuroscience products doubled year over year in Q3 2026. That creates opportunities for diversification and reduces the risk that future growth depends entirely on GLP-1s.


98
New cards

Lilly bear case 6 pillars


1. Extremely expensive valuation


2. Falling GLP-1 prices could eventually overwhelm volume growth


3. Heavy dependence on Mounjaro and Zepbound


4. New drugs might not meet expectations


5. Strong headline results can obscure underlying risks


6. Competition is already showing up in the oral GLP-1 market


7: AI Doesn’t meaningfully benefit R&D or optimization

99
New cards

AI benefits for LLY

Better drug discovery from the same R&D budget


AI could boost production speed and optimize capacity, reduce waste, and improve margins on high-demand treatments.


Another cool unpriced Benefit: Lilly’s deep partnerships (such as its multi-year joint venture with Nvidia and specialized AI platforms) allow it to run high-fidelity simulations of biological data, virtually model patient responses, eliminate placebo-group waste, and weed out doomed compounds before entering costly human testing.

100
New cards

How could AI Re-engineer Clinical Trial’s for Lilly

Pharmaceutical clinical trials suffer from a ~90% failure rate. When a drug fails in Phase III, the pharmaceutical company potentially loses billions of dollars in sunk research and development costs.

Could use AI to identify drugs that are likely to fail early

A reliable synthetic control arm using AI and massive historical datasets could eliminate placebo waste.

With AI, Lilly could catch failures early and run leaner trials, Lilly could achieve much higher profit margins on its R&D spending than Wall Street currently expects.